Development of an oral fluid immunoassay to assess past and recent hepatitis E virus (HEV) infection

External link

Original Article

Hepatitis E virus (HEV) is one of the leading global causes of acute viral hepatitis (Labrique et al., 1999; Emerson and Purcell, 2003). HEV infections result in serious morbidity and mortality, particularly among pregnant women (Tsega et al., 1992; Hamid et al., 1996), and have significant economic costs. Epidemics of hepatitis E are particularly problematic in areas of South Asia where seasonal floods lead to frequent contamination of drinking water supplies with HEV (Labrique et al., 2010; Ippagunta et al., 2007). Whereas case-fatality rates in the general population can vary from 0.1%–3.0% in South Asia, elevated mortality (10%–40%) in pregnant women infected with HEV genotype 1 has been demonstrated consistently. HEV infection during pregnancy frequently leads to miscarriage, preterm delivery and poor neonatal survival, stillbirth and neonatal death. Given its well-documented epidemic potential, with tens of thousands of hepatitis E cases reported annually, rapid, reliable diagnostic testing for hepatitis E is important. Rapid and reliable hepatitis E testing during outbreaks and epidemics could trigger preventive interventions (e.g., provision of safe drinking water, vaccination) to reduce the duration and severity of disease (Labrique et al., 2012; Krain et al., 2014).

FULL PUBLICATION


Back to Top

People

Linnea Zimmerman

Dr. Linnea Zimmerman oversees the management and analysis of PMA2020 data and...

Read More

Antonio J. Trujillo

Dr. Antonio Trujillo is an Associate Professor in the Department of...

Read More

Yusra Shawar

Yusra Shawar MPH PhD is an Assistant Scientist in the Department of...

Read More

Anita Vernekar Shankar

Anita Shankar, PhD, is a medical anthropologist with more than 25 years of...

Read More

Events

S
M
T
W
T
F
S
·
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
·
·